Endpoints News | Nachrichten

Zeit	Aktuelle Nachrichten
13:35	FDA rolls out expectations for a looming regulatory shift for insulin and other biologics
12:35	Eli Lilly is going for it again, inking $2B Alzheimer's deal for tau therapies with AC Immune
Di	Amgen enlists Entera in a drug discovery pact; Boehringer brings out the budget ax
Di	Large coalition joins drug lobby in denouncing Trump proposal to import drug prices for Medicare
Di	Clive Meanwell gives way to new CEO as activist investor Alex Denner shakes up The Medicines Company
Di	Freshman lawmakers give J&J CEO Alex Gorsky another unwanted turn in the public spotlight
Di	Black Diamond turns down an open stretch of R&D highway, headed to a showdown with oncogenes
Di	Anti-CD47 gel could stem tumors from resurfacing, study in mice suggests
Di	Too much success? A booming biotech pipeline will spur intense rivalries - analyst
Di	Sue Dillon, Karyn O'Neil steer fledgling Aro Biotherapeutics to $13M debut -- with J&J's blessing
Di	Ionis is focused on treating the untreatable with medical breakthroughs for patients
Mo	Shanghai Junshi Biosciences next to test HKEX listing; With one eye on Sage, Marinus reports prelim PPD data
Mo	WuXi AppTec starts a global wave of expansion, jumping off in San Diego following $1B Hong Kong IPO raise
Mo	Nasdaq celebrates record biotech IPO success in 2018. But can the party on Wall Street rumba on?
Mo	AstraZeneca, Cancer Research UK set up genomics hub to fight uphill battle against cancer
Mo	0-for-2: Another faded drug star in Axovant's much-hyped pipeline falls, tarnishing Ramaswamy's deal-making rep
Mo	FDA slaps partial hold on MacroGenics for bispecific cancer trials as liver tox spurs safety fears
Mo	Gilead locks in Daniel O'Day as CEO, tapping the Roche vet to rejuvenate growth
Mo	With fresh company building lessons from Ablynx, Edwin Moses is ready to try it again as chair of neoantigen biotech Achilles
Fr	Sanofi will eliminate 670 jobs in France; Moderna gets FDA orphan status for preclinical asset
Fr	Delay brings success for Roche as it finally wins FDA nod for Tecentriq regimen in frontline lung cancer
Fr	Bristol-Myers vet Caroline Loew heads up Glympse Bio; Kaleido nabs GSK's CMO Katharine Knobil
Fr	FDA will allow observational studies as part of a push for real world evidence, new framework says
Fr	Accused of milking the CMS with co-pay kickbacks, J&J's Actelion settles case for $310M
Fr	AstraZeneca's prized Imfinzi/tremelimumab combo fails again - this time in head and neck cancer

Zeit

Aktuelle Nachrichten

13:35

FDA rolls out expectations for a looming regulatory shift for insulin and other biologics

12:35

Eli Lilly is going for it again, inking $2B Alzheimer's deal for tau therapies with AC Immune

Amgen enlists Entera in a drug discovery pact; Boehringer brings out the budget ax

Large coalition joins drug lobby in denouncing Trump proposal to import drug prices for Medicare

Clive Meanwell gives way to new CEO as activist investor Alex Denner shakes up The Medicines Company

Freshman lawmakers give J&J CEO Alex Gorsky another unwanted turn in the public spotlight

Black Diamond turns down an open stretch of R&D highway, headed to a showdown with oncogenes

Anti-CD47 gel could stem tumors from resurfacing, study in mice suggests

Too much success? A booming biotech pipeline will spur intense rivalries - analyst

Sue Dillon, Karyn O'Neil steer fledgling Aro Biotherapeutics to $13M debut -- with J&J's blessing

Ionis is focused on treating the untreatable with medical breakthroughs for patients

Shanghai Junshi Biosciences next to test HKEX listing; With one eye on Sage, Marinus reports prelim PPD data

WuXi AppTec starts a global wave of expansion, jumping off in San Diego following $1B Hong Kong IPO raise

Nasdaq celebrates record biotech IPO success in 2018. But can the party on Wall Street rumba on?

AstraZeneca, Cancer Research UK set up genomics hub to fight uphill battle against cancer

0-for-2: Another faded drug star in Axovant's much-hyped pipeline falls, tarnishing Ramaswamy's deal-making rep

FDA slaps partial hold on MacroGenics for bispecific cancer trials as liver tox spurs safety fears

Gilead locks in Daniel O'Day as CEO, tapping the Roche vet to rejuvenate growth

With fresh company building lessons from Ablynx, Edwin Moses is ready to try it again as chair of neoantigen biotech Achilles

Sanofi will eliminate 670 jobs in France; Moderna gets FDA orphan status for preclinical asset

Delay brings success for Roche as it finally wins FDA nod for Tecentriq regimen in frontline lung cancer

Bristol-Myers vet Caroline Loew heads up Glympse Bio; Kaleido nabs GSK's CMO Katharine Knobil

FDA will allow observational studies as part of a push for real world evidence, new framework says

Accused of milking the CMS with co-pay kickbacks, J&J's Actelion settles case for $310M

AstraZeneca's prized Imfinzi/tremelimumab combo fails again - this time in head and neck cancer

Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und mit der Push-Technologie von

Indizes	Kurs	%	News 24 h / 7 T	Aufrufe 7 Tage

Aktien	Kurs	%	News 24 h / 7 T	Aufrufe 7 Tage

Xetra-Orderbuch

Devisen	Kurs	%

Rohstoffe	Kurs	%

Passende Knock-Outs zu Ihrer Suchanfrage (Anzeige)

Aktuelle News von Endpoints News